← All trials
NCT04283578
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2020
- Primary completion
- Feb 25, 2020
- Completion date
- Dec 31, 2021
- First posted
- Feb 25, 2020
- Last posted
- Mar 2, 2020
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of ToulouseLead sponsor
- Epidemiological and Clinical Research Information NetworkCollaborator
- International Clinical Trials AssociationCollaborator
- University of ToulouseOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.